About Serine/threonine-protein kinase/endoribonuclease IRE2
Serine/threonine-protein kinase/endoribonuclease IRE2 (ERN2) is a protein
from Homo sapiens identified by UniProt accession
Q76MJ5, 926 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | Serine/threonine-protein kinase/endoribonuclease IRE2 |
|---|
| UniProt accession | Q76MJ5 |
|---|
| Gene | ERN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 926 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (50)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- mean corpuscular volume · score 0.16
- inflammatory bowel disease · score 0.11
- mean reticulocyte volume · score 0.10
- neoplasm · score 0.08
- HER2 Positive Breast Carcinoma · score 0.08
- Autosomal recessive early-onset inflammatory bowel disease · score 0.07
- gastroesophageal reflux disease · score 0.06
- breast neoplasm · score 0.06
- inflammatory bowel disease 30 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q76MJ5-F1 | alphafold | PREDICTED | 70.37 | — |
Amino-acid sequence (926 residues)
MASAVRGSRP WPRLGLQLQF AALLLGTLSP QVHTLRPENL LLVSTLDGSL HALSKQTGDL KWTLRDDPVI EGPMYVTEMA FLSDPADGSL YILGTQKQQG LMKLPFTIPE LVHASPCRSS DGVFYTGRKQ DAWFVVDPES GETQMTLTTE GPSTPRLYIG RTQYTVTMHD PRAPALRWNT TYRRYSAPPM DGSPGKYMSH LASCGMGLLL TVDPGSGTVL WTQDLGVPVM GVYTWHQDGL RQLPHLTLAR DTLHFLALRW GHIRLPASGP RDTATLFSTL DTQLLMTLYV GKDETGFYVS KALVHTGVAL VPRGLTLAPA DGPTTDEVTL QVSGEREGSP STAVRYPSGS VALPSQWLLI GHHELPPVLH TTMLRVHPTL GSGTAETRPP ENTQAPAFFL ELLSLSREKL WDSELHPEEK TPDSYLGLGP QDLLAASLTA VLLGGWILFV MRQQQPQVVE KQQETPLAPA DFAHISQDAQ SLHSGASRRS QKRLQSPSKQ AQPLDDPEAE QLTVVGKISF NPKDVLGRGA GGTFVFRGQF EGRAVAVKRL LRECFGLVRR EVQLLQESDR HPNVLRYFCT ERGPQFHYIA LELCRASLQE YVENPDLDRG GLEPEVVLQQ LMSGLAHLHS LHIVHRDLKP GNILITGPDS QGLGRVVLSD FGLCKKLPAG RCSFSLHSGI PGTEGWMAPE LLQLLPPDSP TSAVDIFSAG CVFYYVLSGG SHPFGDSLYR QANILTGAPC LAHLEEEVHD KVVARDLVGA MLSPLPQPRP SAPQVLAHPF FWSRAKQLQF FQDVSDWLEK ESEQEPLVRA LEAGGCAVVR DNWHEHISMP LQTDLRKFRS YKGTSVRDLL RAVRNKKHHY RELPVEVRQA LGQVPDGFVQ YFTNRFPRLL LHTHRAMRSC ASESLFLPYY PPDSEARRPC PGATGR
Explore Serine/threonine-protein kinase/endoribonuclease IRE2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets